4
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T10464 | Atuveciclib | BAY-1143572 | CDK |
Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1]. | |||
T10464L | Atuveciclib Racemate | BAY-1143572 Racemate | CDK |
Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib, which is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM. | |||
T10465 | Atuveciclib S-Enantiomer | BAY-1143572 S-Enantiomer | CDK |
Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is the (S)-enantiomer of BAY-1143572. Atuveciclib S-Enantiomer is a potent and selective CDK9 inhibitor, which inhibits CDK9 / CycT1 with an IC 50 of 16 nM. | |||
T70897 | Zotiraciclib HCl | ||
Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting M... |